<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01137123</url>
  </required_header>
  <id_info>
    <org_study_id>2007044</org_study_id>
    <nct_id>NCT01137123</nct_id>
  </id_info>
  <brief_title>Improve the Treatment of Thoracic Esophageal Cancer</brief_title>
  <official_title>A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is

        1. To compare the effects of the two types of thoracic esophageal cancer lymphadenectomy on
           the staging and prognosis of resectable esophageal cancer, which defined by the
           International Association of esophageal disease(ISDE) - standard mediastinal
           lymphadenectomy,total mediastinal lymphadenectomy and three field lymphadenectomy,and to
           find out reasonable range of lymphadenectomy.

        2. To compare the effects of Chemotherapy Group (Docetaxel + Nedaplatin) with Control Group
           on the prognosis of resectable thoracic esophageal cancer,and to explore the indications
           of adjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to different location of the primary lesion，the subject can be allocated to two
      sub-groups:

      The patient with upper or middle thoracic esophageal cancer may be assigned to two
      field(T)-total mediastinal lymphadenectomy group,which is control group in this study or
      three field lymphadenectomy-Abdominal + mediastinal + cervical lymphadenectomy group,which is
      study group in this study randomly.

      After the operation,the patient whose primary lesion is completely(R0) resected will be
      assigned to adjuvant chemotherapy group or interview group randomly.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>survival rate</measure>
    <time_frame>5 years</time_frame>
    <description>Disease-free survival
overall survival</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Thoracic Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>standard two field +follow-up</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>standard two field +adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>total two field+follow-up</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>total two field+adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>three field+follow-up</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>three field+adjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adjuvant chemotherapy</intervention_name>
    <description>Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.</description>
    <arm_group_label>standard two field +adjuvant chemotherapy</arm_group_label>
    <arm_group_label>total two field+adjuvant chemotherapy</arm_group_label>
    <arm_group_label>three field+adjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard two field Lymphadenectomy</intervention_name>
    <description>Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.</description>
    <arm_group_label>standard two field +follow-up</arm_group_label>
    <arm_group_label>standard two field +adjuvant chemotherapy</arm_group_label>
    <other_name>two field(S)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total two field Lymphadenectomy</intervention_name>
    <description>Total two field Lymphadenectomy is total mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.</description>
    <arm_group_label>total two field+follow-up</arm_group_label>
    <arm_group_label>total two field+adjuvant chemotherapy</arm_group_label>
    <other_name>two field(T)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>three field Lymphadenectomy</intervention_name>
    <description>Three field Lymphadenectomy includes abdominal,mediastinal and cervical lymphadenectomy.</description>
    <arm_group_label>three field+follow-up</arm_group_label>
    <arm_group_label>three field+adjuvant chemotherapy</arm_group_label>
    <other_name>three field</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age≤70 years old;

          2. Karnofsky Performance Status（KPS）≥80;

          3. Pathological diagnosis is squamous cell carcinoma of thoracic esophageal which is
             treated initially;

          4. Clinical stage is c T 1 ~ 3 N 0 ~ 1 according to the results of endoscopic
             ultrasonography，chest and abdomen CT and neck ultrasonic.

          5. The preoperative evaluation of organ function is tolerant of surgery and chemotherapy;

          6. The subject can understand and sign the informed consent form (ICF);

          7. The following laboratory tests, made in 4 weeks before first medication, confirmed
             that bone marrow, liver and kidney function in line with the requirements to
             participate in research; Hemoglobin（HGB）≥9.0g/L; absolute neutrophils
             count（ANC）≥1.5×109/L; platelet count（PLT）≥100×109/L; total
             bilirubin（TBIL）≤1.5N;aspartate aminotransferase (AST)≤2.5N;alanine
             aminotransferase(ALT)≤2.5N;prothrombin time(PT)≤1.5N, and activated partial
             thromboplastin time(APTT) is in normal range;endogenous creatinine clearance
             rate(CRE)≤1.5N.

        Exclusion Criteria:

          1. Cervical esophageal cancer and Non-squamous cell carcinoma of thoracic esophageal
             cancer;

          2. Advanced Esophageal Cancer;

          3. Prior malignancy in 5 years recently;

          4. History of previous chest radiotherapy;

          5. History of cardio-cerebral vascular accident in 6 months lately;

          6. The subject can not understand and sign the informed consent form(ICF).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peng Lin, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>651, Dongfeng Road East, Guangzhou, P. R. China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng Ling, professor</last_name>
    <phone>+86-20-87343314</phone>
    <email>linpeng@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tan Zi Hui</last_name>
    <phone>+86-20-87343736</phone>
    <email>tanzh@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen Uniersity Cancer Center</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peng Lin, Professor</last_name>
      <phone>+86-20-87343314</phone>
      <email>linpeng@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jun Zeng</last_name>
      <phone>+86-20-87343736</phone>
      <email>xingrp@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Peng Lin, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.sysucc.com</url>
  </link>
  <reference>
    <citation>Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66. Review.</citation>
    <PMID>11602373</PMID>
  </reference>
  <reference>
    <citation>Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2002 Mar;183(3):274-9.</citation>
    <PMID>11943125</PMID>
  </reference>
  <reference>
    <citation>Peracchia A, Bonavina L, Ruol A, Stein H. Esophageal cancer: a European perspective. Recent Results Cancer Res. 2000;155:119-22.</citation>
    <PMID>10693245</PMID>
  </reference>
  <reference>
    <citation>Isono K, Sato H, Nakayama K. Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology. 1991;48(5):411-20.</citation>
    <PMID>1745490</PMID>
  </reference>
  <reference>
    <citation>Kato H, Watanabe H, Tachimori Y, Iizuka T. Evaluation of neck lymph node dissection for thoracic esophageal carcinoma. Ann Thorac Surg. 1991 Jun;51(6):931-5.</citation>
    <PMID>2039322</PMID>
  </reference>
  <reference>
    <citation>Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg. 1998 Jan;175(1):47-51.</citation>
    <PMID>9445239</PMID>
  </reference>
  <reference>
    <citation>Watanabe H. [Necessity of cervical lymph node dissection by retrospective analysis of submucosal cancer in mid-thoracic esophagus]. Nihon Geka Gakkai Zasshi. 1997 Sep;98(9):733-6. Review. Japanese.</citation>
    <PMID>9370130</PMID>
  </reference>
  <reference>
    <citation>Law SY, Fok M, Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg. 1996 Jan;83(1):107-11.</citation>
    <PMID>8653330</PMID>
  </reference>
  <reference>
    <citation>Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1727-33.</citation>
    <PMID>12049861</PMID>
  </reference>
  <reference>
    <citation>Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998 Dec 31;339(27):1979-84.</citation>
    <PMID>9869669</PMID>
  </reference>
  <reference>
    <citation>Polee MB, Tilanus HW, Eskens FA, Hoekstra R, Van der Burg ME, Siersema PD, Stoter G, Van der Gaast A. Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus. Ann Oncol. 2003 Aug;14(8):1253-7.</citation>
    <PMID>12881388</PMID>
  </reference>
  <reference>
    <citation>Keresztes RS, Port JL, Pasmantier MW, Korst RJ, Altorki NK. Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial. J Thorac Cardiovasc Surg. 2003 Nov;126(5):1603-8.</citation>
    <PMID>14666040</PMID>
  </reference>
  <reference>
    <citation>Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol. 2002 Jun;42(3):317-25. Review.</citation>
    <PMID>12050023</PMID>
  </reference>
  <reference>
    <citation>Yamanaka H, Motohiro T, Michiura T, Asai A, Mori T, Hioki K. Nedaplatin and 5-FU combined with radiation in the treatment for esophageal cancer. Jpn J Thorac Cardiovasc Surg. 1998 Oct;46(10):943-8.</citation>
    <PMID>9847566</PMID>
  </reference>
  <reference>
    <citation>Yoshioka T, Gamoh M, Shineha R, Ishibashi S, Shibata H, Suzuki T, Murakawa Y, Kato S, Shimodaira H, Kato S, Ishioka C, Kanamaru R. A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers. Intern Med. 1999 Nov;38(11):844-8.</citation>
    <PMID>10563743</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2010</study_first_submitted>
  <study_first_submitted_qc>June 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2010</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Peng Lin</investigator_full_name>
    <investigator_title>Sun Yat-sen University Cancer Center</investigator_title>
  </responsible_party>
  <keyword>esophageal squamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

